AstraZeneca’s top-selling drug Tagrisso is already widely used on its own as a first-line treatment for EGFR-mutated lung cancer, but new data suggests there can be benefi
Johnson & Johnson’s consumer health unit Kenvue looks set to raise $3.8 billion in an upsized initial public offering (IPO), valuing the business at around $41 billion
Johnson & Johnson’s appetite for building a new generation of CAR-T therapies for cancer shows no sign of being sated – its Janssen Biotech unit has just paid $245 mil
Johnson & Johnson has picked up its first regulatory approval worldwide for Akeega, a fixed-dose combination of a PARP inhibitor and anti-androgen therapy, as a treatm
Patients in England with chronic lymphocytic leukaemia (CLL) will be able to access a new combination therapy based on Johnson & Johnson’s Imbruvica plus AbbVie’s Venc
Johnson & Johnson was preparing to divulge the data from its eagerly-awaited CARTITUDE-4 trial of CAR-T therapy Carvykti later this year, but a leak of the data has gi